PureTech, Boehringer partner to develop lymph node-targeting cancer immunotherapies

As part of its shift to focus on an internal pipeline in lieu of its previous affiliate model, PureTech partnered its lymphatic targeting platform with Boehringer Ingelheim Wednesday. The partners will initially use the platform to deliver an undisclosed candidate from Boehringer's pipeline directly to the the gut lymphatics to treat GI cancers.